BRPI0817269A2 - Análogos de azacitidina e usos dos mesmos - Google Patents

Análogos de azacitidina e usos dos mesmos

Info

Publication number
BRPI0817269A2
BRPI0817269A2 BRPI0817269-2A2A BRPI0817269A BRPI0817269A2 BR PI0817269 A2 BRPI0817269 A2 BR PI0817269A2 BR PI0817269 A BRPI0817269 A BR PI0817269A BR PI0817269 A2 BRPI0817269 A2 BR PI0817269A2
Authority
BR
Brazil
Prior art keywords
azacitidine
analogs
azacitidine analogs
Prior art date
Application number
BRPI0817269-2A2A
Other languages
English (en)
Inventor
Lewis Silverman
James Holland
Original Assignee
Sinai School Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinai School Medicine filed Critical Sinai School Medicine
Publication of BRPI0817269A2 publication Critical patent/BRPI0817269A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12Triazine radicals
BRPI0817269-2A2A 2007-09-26 2008-09-25 Análogos de azacitidina e usos dos mesmos BRPI0817269A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97543707P 2007-09-26 2007-09-26
PCT/US2008/077669 WO2009042766A1 (en) 2007-09-26 2008-09-25 Azacytidine analogues and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0817269A2 true BRPI0817269A2 (pt) 2014-10-07

Family

ID=40511851

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0817234-0A2A BRPI0817234A2 (pt) 2007-09-26 2008-09-25 Análogos de azacitidina e seus usos
BRPI0817269-2A2A BRPI0817269A2 (pt) 2007-09-26 2008-09-25 Análogos de azacitidina e usos dos mesmos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0817234-0A2A BRPI0817234A2 (pt) 2007-09-26 2008-09-25 Análogos de azacitidina e seus usos

Country Status (15)

Country Link
US (2) US8399420B2 (pt)
EP (2) EP2205073A4 (pt)
JP (2) JP2010540555A (pt)
KR (2) KR20100102092A (pt)
CN (2) CN101877964A (pt)
AU (2) AU2008304380A1 (pt)
BR (2) BRPI0817234A2 (pt)
CA (2) CA2700267A1 (pt)
IL (1) IL204690A0 (pt)
MX (2) MX2010003261A (pt)
NZ (2) NZ583824A (pt)
RU (1) RU2488591C2 (pt)
UA (2) UA99836C2 (pt)
WO (2) WO2009042767A1 (pt)
ZA (1) ZA201001660B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497292B2 (en) 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
NZ583824A (en) * 2007-09-26 2012-06-29 Sinai School Medicine Azacytidine analogues and uses thereof
SG193206A1 (en) 2008-05-15 2013-09-30 Celgene Corp Oral formulations of cytidine analogs and methods of use thereof
EP2321302B1 (en) 2008-08-01 2014-10-29 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
AR076418A1 (es) * 2009-04-27 2011-06-08 Reddys Lab Inc Dr Preparacion de decitabina
CA2825152A1 (en) 2011-01-31 2012-08-09 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
US20120264710A1 (en) * 2011-04-15 2012-10-18 Marit Liland Sandvold Systems and Methods for Detecting hENT1 Expression in Hematological Disorders
JP6162709B2 (ja) 2011-11-01 2017-07-12 セルジーン コーポレイション シチジンアナログの経口製剤を使用して癌を治療する方法
KR102064626B1 (ko) 2012-02-24 2020-01-09 시그날 파마소티칼 엘엘씨 Tor 키나제 억제자 복합 치료법을 사용한 비소세포 폐암의 치료 방법
US9493500B2 (en) 2012-07-19 2016-11-15 Richard Daifuku Fluorinated pyrimidine analogs and methods of use thereof
US9782427B2 (en) * 2013-04-17 2017-10-10 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
WO2015195786A2 (en) 2014-06-17 2015-12-23 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
WO2017090264A1 (ja) 2015-11-27 2017-06-01 大原薬品工業株式会社 5-アザシチジン又は其の2'-デオキシ体の5'位ジベンジル燐酸エステル
EP3960182A1 (en) 2015-12-03 2022-03-02 Epidestiny, Inc. Compositions containing decitabine, 5-azacytidine and tetrahydrouridine and uses thereof
WO2018175179A1 (en) 2017-03-20 2018-09-27 Vaccinex, Inc. Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent
EA202090103A1 (ru) 2017-06-22 2020-04-24 Селджин Корпорейшн Лечение гепатоцеллюлярной карциномы, которая характеризуется вирусной инфекцией гепатита b
CA3097003A1 (en) * 2018-04-19 2019-10-24 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer
US20230416294A1 (en) * 2020-08-10 2023-12-28 The Johns Hopkins University Decitabine analogs for immunological and oncological therapy

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE612384A (fr) 1961-01-10 1962-05-02 Spofa Vereinigte Pharma Werke Procédé de préparation des 1-glycosyle-6-aza-uraciles
GB1050899A (pt) * 1963-12-22
DE2012888C3 (de) 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
DE2122991C2 (de) * 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
US3984396A (en) 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US3998807A (en) * 1972-03-03 1976-12-21 Syntex (U.S.A.) Inc. Arabinofuranosyl cytosines and methods of making
US4172889A (en) * 1976-03-29 1979-10-30 The Upjohn Company Method of treating rheumatoid arthritis
US4405611A (en) * 1980-06-27 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services Bisulfite stabilization of 5-azacytidine
DE3100478A1 (de) 1981-01-09 1982-08-12 Dr. Thilo & Co GmbH, 8021 Sauerlach 5'ester von pyrimidinnucleosiden mit antiviraler wirksamkeit, verfahren zur herstellung und daraus hergestellte arzneimittel
SU961354A1 (ru) * 1981-02-18 1985-08-07 Институт биоорганической химии АН БССР 3-Фтор-2,3-дидезоксиаденозин,про вл ющий цитостатическую активность
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
DE3737456A1 (de) 1986-11-04 1988-05-19 Fuji Photo Film Co Ltd Laserlichtquelle
CS264454B1 (cs) 1987-08-28 1989-08-14 Piskala Alois 2'-Deoxy-5,6-dihydro-5-azacytidin a způsob jeho výroby
CS264456B1 (cs) 1987-08-28 1989-08-14 Piskala Alois Způsob výroby 5,6-dihydro-S-azacytidinu
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US4984396A (en) * 1988-08-29 1991-01-15 Uragami Fukashi Cleaning device
DE3834435A1 (de) * 1988-10-10 1990-06-13 Basf Ag Verbrueckte, wasserloesliche copolymerisate, verfahren zu ihrer herstellung und ihre verwendung
US5216142A (en) 1989-04-17 1993-06-01 Efamol Holdings Plc Anti-virals
JP2559917B2 (ja) * 1990-06-15 1996-12-04 三共株式会社 ピリミジンヌクレオシド誘導体
DE4026265A1 (de) 1990-08-20 1992-02-27 Boehringer Mannheim Gmbh Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel
DE69219236T2 (de) * 1991-02-19 1997-08-07 Fujitsu Ltd Halbleiteranordnung mit einem mit sauerstoff angereicherten gebiet und deren herstellungsverfahren
US5385912A (en) * 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
DK0599968T3 (da) * 1991-08-14 2000-04-17 Procter & Gamble Pharma Oxazolidinonderivater, der er egnede som antiarytmi- og antifibrilleringsmidler
GB2260319B (en) * 1991-10-07 1995-12-06 Norsk Hydro As Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity
GB9307043D0 (en) * 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
GB9515279D0 (en) 1995-07-25 1995-09-20 Norsk Hydro As Improved therapeutic agents
DE19505168A1 (de) * 1995-02-16 1996-08-22 Boehringer Mannheim Gmbh Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
WO1997005143A1 (fr) 1995-07-25 1997-02-13 Asahi Kasei Kogyo Kabushiki Kaisha Nouveaux composes a base de metaux de transition du groupe 4
JPH11510697A (ja) * 1995-08-08 1999-09-21 トーマス ジェファソン ユニバーシティー 組換え体c−プロテイナーゼ、ならびにそのプロセス、方法および使用
US5760063A (en) 1995-09-15 1998-06-02 Scriptgen Pharmaceuticals, Inc. Arylhydrazone derivatives useful as antibacterial agents
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
DK0914116T3 (da) * 1996-05-22 2000-11-20 Protarga Inc Kompositstoffer omfattende konjugater af cis-docosahexaensyre og Taxotere
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
JPH10158192A (ja) * 1996-10-03 1998-06-16 Eisai Co Ltd 移植片対宿主疾患(gvhd)の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物
GB2321455A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
KR100483256B1 (ko) * 1997-01-24 2005-04-15 콘파마 아에스 젬시타빈 유도체
US6498149B1 (en) * 1997-06-03 2002-12-24 Tsuneatsu Mori Natural antitumor or antiviral substances and use of the same
AU1412299A (en) 1997-11-25 1999-06-15 Protarga, Inc. Nucleoside analog compositions and uses thereof
AU2300699A (en) 1998-02-17 1999-08-30 Ono Pharmaceutical Co. Ltd. Amidino derivatives and drugs containing the same as the active ingredient
AU5073100A (en) 1999-06-09 2001-01-02 Bayer Aktiengesellschaft Pyridine carboxamides and their use as plant protection agents
EP1210354A1 (en) 1999-09-08 2002-06-05 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
NZ517999A (en) * 1999-10-15 2004-07-30 F Benzodiazepine derivatives
US6670341B1 (en) 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells
CA2468099A1 (en) 2001-11-21 2003-05-30 Ganymed 256 Vermogensverwaltungs Gmbh Phospholipid derivatives of nucleosides as antitumoral medicaments
US6998391B2 (en) * 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
US7772197B2 (en) 2002-09-24 2010-08-10 1,3,5-Triazines for Treatment of Viral Diseases 1,3,5-triazines for treatment of viral diseases
US7038038B2 (en) * 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
WO2004101593A1 (ja) 2003-05-16 2004-11-25 Kissei Pharmaceutical Co., Ltd. 5’−修飾ヌクレオシド誘導体及びその医薬用途
US7244732B2 (en) * 2003-06-20 2007-07-17 Koronis Pharmaceuticals, Incorporated Prodrugs of heteroaryl compounds
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
JP2007537999A (ja) 2003-12-19 2007-12-27 コローニス ファーマシューティカルズ インコーポレイテッド 変異原性複素環
WO2005066162A1 (en) 2003-12-23 2005-07-21 Human Biomolecular Research Institute Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer
CA2555311A1 (en) 2004-02-04 2005-08-18 Neurosearch A/S Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands
US7192781B2 (en) 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
WO2005115410A2 (en) 2004-05-06 2005-12-08 University Of Rochester Context dependent inhibitors of cytidine deaminases and uses thereof
GB0419416D0 (en) 2004-09-01 2004-10-06 Inst Of Ex Botany Ascr 4-Arylazo-3,5-Diamino-Pyrazole compounds and use thereof
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
EP1809620B1 (en) 2004-11-04 2010-12-29 Addex Pharma SA Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
EP1937283A2 (en) * 2005-09-19 2008-07-02 Celator Pharmaceuticals, Inc. Combination formulations of cytidine analogs and platinum agents
KR101289995B1 (ko) 2005-09-27 2013-07-26 시오노기 앤드 컴파니, 리미티드 Pgd2 수용체 길항제 활성을 갖는 설폰아마이드 유도체
NO324263B1 (no) 2005-12-08 2007-09-17 Clavis Pharma Asa Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser
US20070225248A1 (en) 2006-03-21 2007-09-27 Clavis Pharma As Oral dosage forms of gemcitabine derivatives
NZ583824A (en) 2007-09-26 2012-06-29 Sinai School Medicine Azacytidine analogues and uses thereof

Also Published As

Publication number Publication date
US20090209477A1 (en) 2009-08-20
CN101815437A (zh) 2010-08-25
EP2197274A4 (en) 2013-03-06
JP2010540556A (ja) 2010-12-24
NZ583824A (en) 2012-06-29
WO2009042766A1 (en) 2009-04-02
KR20100072230A (ko) 2010-06-30
CA2700267A1 (en) 2009-04-02
ZA201001660B (en) 2011-05-25
UA99836C2 (en) 2012-10-10
MX2010003002A (es) 2010-07-05
US8158605B2 (en) 2012-04-17
US20090209482A1 (en) 2009-08-20
NZ583923A (en) 2012-05-25
RU2010116274A (ru) 2011-11-10
KR20100102092A (ko) 2010-09-20
RU2488591C2 (ru) 2013-07-27
AU2008304380A1 (en) 2009-04-02
WO2009042766A9 (en) 2009-05-28
BRPI0817234A2 (pt) 2014-09-30
IL204690A0 (en) 2010-11-30
JP2010540555A (ja) 2010-12-24
CA2700207A1 (en) 2009-04-02
AU2008304381A1 (en) 2009-04-02
EP2197274A1 (en) 2010-06-23
RU2010116154A (ru) 2011-11-10
US8399420B2 (en) 2013-03-19
MX2010003261A (es) 2010-08-18
EP2205073A1 (en) 2010-07-14
WO2009042767A1 (en) 2009-04-02
EP2205073A4 (en) 2013-03-06
UA99308C2 (ru) 2012-08-10
CN101877964A (zh) 2010-11-03

Similar Documents

Publication Publication Date Title
BRPI0817269A2 (pt) Análogos de azacitidina e usos dos mesmos
BRPI0922691A2 (pt) conjugados de leptina e análogo de leptina e usos dos mesmos
BRPI0920927A2 (pt) derivados de azaquinolinona e usos dos mesmos
BRPI0923283A2 (pt) conjugados terapêuticos de peptídeo e usos dos mesmos
BRPI0922689A2 (pt) conjugados de neurotensina ou análogos de neurotensina e usos dos mesmos
BRPI0914682A2 (pt) compostos de heteroarila e usos dos mesmos
BRPI0821310A2 (pt) Conjugados polipeptídeos-ácido nucleico e usos dos mesmos
BRPI0819909A2 (pt) anticorpos antimesotelina e usos dos mesmos
BRPI0912480A2 (pt) compostos de monoalquiltina de alta pureza e usos dos mesmos
BRPI0912198A2 (pt) anticorpos anti-fn14 e usos dos mesmos
BRPI0821106A2 (pt) Pró-fármacos de nucleosídeo e usos dos mesmos
BRPI1015918A2 (pt) conjugados de peptídeo multiméricos e usos dos mesmos
BRPI1013943A2 (pt) Composto cetais e usos dos mesmos.
BRPI0814599A2 (pt) Pesticidas e usos dos mesmos
BRPI0914891A2 (pt) agonistas de aril gpr119 e usos dos mesmos
BRPI0813647A2 (pt) Piperazinil oxoalquil tetrahidro-beta-carbolinas e análogos relacionados
BRPI0720494A2 (pt) Dispositivo de suporte vertebral
BRPI1014997A2 (pt) compostos heteroarila e usos dos mesmos
BRPI0922483A2 (pt) agonista de receptor gpr120 e usos dos mesmos
DK2066354T3 (da) Norovirus vaccine formuleringer
DK2051744T3 (da) Steriliseringsanordning
BRPI0922790A2 (pt) peptídeos de ligação sparc e usos dos mesmos
BRPI0909469A2 (pt) compostos de oximetileno de arila e usos dos mesmos
BRPI0807544A2 (pt) Sólido farmacêutico e dose de vacina
BRPI1009455A2 (pt) anticorpos anti-c40 e usos dos mesmos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.